Group 1 - The Hong Kong Innovative Drug ETF (513120) increased by 1.28% on February 4, with a trading volume of 4.119 billion yuan [1] - The fund's shares rose by 12.4 million, bringing the total shares to 19.699 billion, with an increase of 42.9 million shares over the last 20 trading days [1] - The latest net asset value of the fund is 24.746 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Innovative Drug ETF is the return rate of the China Securities Hong Kong Innovative Drug Index (calculated in RMB) [1] - The fund is managed by Guangfa Fund Management Co., Ltd., with Liu Jie as the fund manager [1] - Since its establishment on July 1, 2022, the fund has achieved a return of 25.61%, with a return of 4.54% over the past month [1]
2月4日港股创新药ETF（513120）份额增加1.24亿份
Xin Lang Cai Jing·2026-02-05 01:04